Concepedia

Rashmi K. Murthy

RK

Statistics

Publications

59

Citations

6.4K

H-Index

31

Active since

2009

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Dana-Farber Cancer Institute

Baylor College of Medicine

University of Colorado Denver

Seagen (United States)

Rashmi K. Murthy is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2009–2025

59

Publications

59

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

, , +12

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy et al. · Journal of Clinical Oncology · 2020 · 817 citations · Full text

, , +17

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Nancy U. Lin, Virginia F. Borges, Carey K. Anders et al. · Journal of Clinical Oncology · 2020 · 549 citations · Full text

, , +17

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Bruno V. Sinn, Chunxiao Fu, Rosanna Lau et al. · npj Breast Cancer · 2019 · 355 citations · Full text

, , +17

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura, Junji Tsurutani, Shunji Takahashi et al. · The Lancet Oncology · 2019 · 350 citations

, , +16

1–5 of 59